Access cutting-edge advanced cancer treatment through this clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.
Access advanced cancer specialists in Duarte at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced cancer treatment provided free
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin
Sponsor: Turning Point Therapeutics, Inc.
Check if you qualify for this advanced cancer clinical trial in Duarte, CA
If you're searching for advanced cancer treatment options in Duarte, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Duarte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.